Cullinan Oncology emerged nearly three years ago with an approach to cancer drugs its founders said would improve the odds of success. Now it has a pipeline of seven compounds and a fresh $98.5 million to advance all of them.
The... Read more »
AstraZeneca is looking to bolster its cancer R&D portfolio with therapies that target RNA-modifying enzymes and other proteins involved in cancer. On Thursday the Cambridge, UK-based pharma giant announced it would pay Boston-area biotech Accent Therapeutics $55 million up front to... Read more »
The early bird sale for Xcelerating Life Sciences San Francisco: The AI, Big Data, and R&D Boom ends this Friday at 11:59 p.m. PT. Register today to lock in the low $99 rate and secure your spot at the online forum... Read more »
Our immune systems are designed to monitor for signs of foreign molecules, and among the first responses to such signals of potential danger are the formation of structures called inflammasomes.
But the innate immune system’s natural inflammatory reaction, a protective mechanism... Read more »
Chinook Therapeutics and Aduro Biotech, each pursuing different approaches to the same rare disease, are now converging on a path to combine their operations into a single company focused on developing new treatments for kidney disorders.
The merger agreement announced Tuesday... Read more »
Four years after Regeneron Pharmaceuticals and Intellia Therapeutics began working together to research the use of CRISPR/Cas9 to treat liver diseases, the partners are expanding their pact to bleeding disorders.
The deal announced Monday covers the development of potential treatments for... Read more »
Forma Therapeutics has developed a pipeline of small molecules aimed at rare blood disorders and cancers, but it aims to advance two—investigational treatments for sickle cell disease and for advanced prostate cancer—and find partners for the rest of them.
Now the... Read more »
An AbbVie drug that treats pain in the uterus has notched an additional FDA approval for addressing heavy menstrual bleeding associated with uterine fibroids.
The regulatory decision Friday covers that drug, elagolix, combined with estrogen and progestin in a capsule that... Read more »
Human DNA holds secrets that, once uncovered, have led scientists to develop a number of treatments for disease. A slew of biopharmas and biotechs—not to mention national health systems—have hoovered up genetic data from millions of people in hopes of leveraging... Read more »
The US FDA’s formal guidance on development of COVID-19 treatments and preventative agents takes a broadly flexible approach to Phase 2 and 3 trial design, repeatedly indicating a willingness to consider varied options while urging sponsors to discuss their trials plans... Read more »
Most of the best-selling drugs worldwide today are antibodies, and in the three decades-plus since the first such drug was approved, makers of such treatments have begun endeavoring to design drugs to tackle ever more difficult classes of therapeutic targets.
Vancouver,... Read more »
Clinicians and regulators are rethinking how healthcare is provided amid precautions prompted by COVID-19. In-person physician visits don’t fit within the physical distancing guidelines that are now the new normal. New technology presents alternatives.
As a digital therapeutics startup, Akili Interactive... Read more »
While treatments for many health conditions have undergone reinvention in the past two decades, birth control options haven’t changed much. On Friday, San Diego-based Evofem Biosciences said it received FDA approval for a new kind of contraceptive: a non-hormonal vaginal gel... Read more »
As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything resembling a pre-pandemic normal without a COVID-19 vaccine.
AMAG Pharmaceuticals wants out of the women’s health business—and now it’s halfway there.
The FDA on Thursday approved a Sunovion Pharmaceuticals treatment for Parkinson’s disease, giving patients a new way to take an old drug.
The Sunovion product, Kynmobi, is a formulation of apomorphine hydrochloride, a drug that treats “off” episodes experienced by Parkinson’s... Read more »
Learn what’s fueling San Diego’s biotech investment and partnership opportunities by downloading Xconomy’s new special report and podcast that package the highlights from the recent Xcelerating Life Sciences San Diego: Biomedical Breakthroughs in Precision Medicine & Genomics event.